KANDLELIT-001 Trial

[Slide 1] ongoing open-label, phase 1 study of calderasib as monotherapy NSCLC) or as KANDLELIT-001: part of combination An therapy (arms with KRAS G12C-mutated metastatic Arms 1+ 3 (N=193 all solid tumors; n=68 NSCLC): Calderasib Monotherapy 25-800 mg/d POª Locally advanced unresectable or metastatic solid tumor 21 prior systemic therapy for advanced disease Key Eligibility Criteria (all arms) Age ≥ 18 years Arm 2 (N=107): Calderasib 25-400 mg/d POª + Pembrolizumabᵇ Histologic or blood-based confirmation of Metastatic NSCLC with PD-L1 TPS ≥1% KRAS G12C mutation No indication for EGFR-, ALK-, or ROS1-directed therapy as primary treatment ECOG PS 0 or 1 No prior therapy for metastatic disease Measurable disease per RECIST v1.1 Arm 4 (N=46): Calderasib 25-400 mg/d POª + Pembrolizumab + Chemotherapy© Metastatic NSCLC with any TPS No indication for EGFR-, ALK-, or ROS1-directed therapy as primary treatment No prior therapy for metastatic disease Primary endpoint: Incidence of DLTs, AEs, and AEs that led to discontinuation Secondary endpoints: ORR and DOR per RECIST v1.1 by investigator assessment; pharmacokinetic measures of calderasib administered as monotherapy or as part of combination therapy 500 ng/ N Q3W carboplatin PDL1 area under the concentration-time curve 5 mg/mL/min administered IV cycles. Chemotherapy Cabbrash POQD or BD for the total daily dose indicated Pembrolizumab 200mg IV Q3W for <35 lesting was not required for enrollment but archival or fresh tumor samples Q3W was for submitted 4 cycles and for pemetrexed each participant Organisers Partners ESMO IASLC INTERNATIONAL ASSOCIATION FOR THE ESTRO I or LUNG I 1 ETOP-IBCSG foundwink lings Hereby I --- [Slide 2] Best change from baseline in target lesion sizeᵃ Total (N=98) TPS 1%-49% (n=44) TPS >50% (n=54) Arms 2: Calderasib + Pembro (TPS >1%) 100 72 (63-81) 55 (39-70) 87 (75-95) ORR % (95% CI) 80 Median TTR (range), months 1.4 (1.2-10.3) 1.4 (1.2-4.2) 1.4 (1.2-10.3) 60 Median DOR (range), months NR (1.4+ to 37.1+) NR (1.4+ to 37.1+) 27.8 (1.5+ to 30.6+) 40 DCR, % (95% CI) 95 (88-98) 93 (81-99) 96 (87-100) 100 Arms 1+3 Calderasib Monotherapy NSCLC Only (N-59) ORR %(95% C) 27 (16-40) Best Change From Baseline in Target Lesion Size, % 20 0 -20 80 Median TTR (range). months 40 60 14(1226) Median DOR (tange) months 23(12+ to 30.6+) -60 40 I I From & li I 40 20 DOR %(%%C) 20 71 (58-82) -80 0 -100 100 Arm 4: Calderasib + Pembro + Chemo Total (N=46) & 80 ORR % (95% CI) 65 (50-79) 80 60 Median TTR (range), months 100 1.5 (1.2-18.1) 40 Median DOR (range), months Best Change From Baseline in Target Lesion Size, % DCR, % (95% CI) NR (1.9+ to 21.1+) 20 89 (76-96) 0 DCR and By who investigabor disease were first review dosed per at RECIST least / weeks v1 1, includes before the all date participants with at postbaseline maging assessment -20 40 DCO TTR date time 05JAN2026 b response control rate DOR duration of response; NR of not data reached, culoff ORR objective response rate; -60 -80 -100 --- [Slide 3] Progression-free survivalᵃ Participants in arm 2 by PD-L1 TPS Participants with NSCLC (arms 1+ 3,2, and 4) 100 12-mo rate 100 12-mo rate 81% 75% 90 90 66% 54% 80 41% 80 / I / 20 30 70 60- Progression-free survival, % 70 60 50 50 40 40 30 6-mo rate 90% 20 10- 82% 6-mo rate 60% 10 0 94% 0 $ 84% 10 15 20 25 30 0 35 40 No. at ml 45 Time (months) 0 5 10 15 Am2 N 20 25 75 $5 30 43 35 Amt - 23 37 14 $ No. risk 40 45 28 12 2 3 0 INSCLC Time (months) . - 0 0 1 0 TPS >50% 54 I 7 0 45 5 2 0 38 0 TPS 1%-49% 44 29 1 32 16 17 10 0 0 2 14 7 0 0 4 3 0 2 0 0 Am 2 Calderasib + pembro YL NSCLC with TPS 21%) Pts With Event Median PFS (95% CI) Am Calderasib + pembro chemo (12 NSCLC: any TPS) 29/98(30%) 28.9(20.6-NR) Arms 1+ Calderasib monotherapy (advanced NSCLC) 19/46(41%) Arm 2 Calderasib + pembro (1L NSCLC with TPS >50%) Pts With Event 15.1(10.5-NR) Median PFS (95% CI) 22/59(37%) 8.3(4.2-18.1) Arm 2 Calderasib + pembro (1L NSCLC with TPS 1%-49%) 15/54 (28%) NR (20.6-NR) 14/44 (32%) 25.1 (9.5-NR) DOO By investigator date 05JAN2026 review per RECIST 1 1, includes participants who were first dosed at least / weeks before the date of data cutoff Organisers ESMO ASLC Partners INTERNATIONAL ASSOCIATION OF LUNG ESTRO I / ETOP-IBCSG --- [Slide 4] Summary of treatment-related adverse events (TRAEs) Arms 3 Arm 2 Arm 4 N=107 N=46 N=193 Arm 4 TRAEs in the safety population* 117 (61) 95 (89) 45 (98) 125 Am 2 Arms w Calderasib . Pembro Chemo Any grade TRAE, n (%) Calderasib Calderasib Pembro IL NSCLC; any TPS 16 (8) 30 (28) 25 (54) 97% Monotherapy 12 NSCLC with TPS 21% №46 Grade 3 1 (<1) 4 (4) 4 (9) AT Sold Tumors №107 Grade 4 30% N-193 0 1 (1)b 1 (2)c Grade 5 Gr12 # $ Q12 G12# G:35 . Led to discontinuation of calderasib 1 (<1) (5) 3(7) Q35 # G35 . 60% Arms 3 Arm 2 Arm 4 / , 50% 48 43 43 DLTs in the DLT-evaluable population N=183 N=102 N=46 39 37 4% 36 35 Any DLT, (%) 2(1) 2(2) 5 (11) 34 32 30 ALT increased (grade 3) 0 1(1) 2 (4) 30% 24 24 22 AST increased (grade 3) 0 1(1) 1 (2)e 20 20 20% 17 17 15 15 15 Blood alkaline phosphate increased 1 (<1) 0 0 12 12 12 11 11 11 11 13 13 13 13 12% Colitis (grade 3) 0 0 (2) Diarrhea (grade 3) 0 0 a 1 (2) AST y is AST ALTT Rash in FORTALPT Anemia 1st HUNDO A 3BM Pruntus Creatine Page GGT ECG QT prolonged (grade 3) 1 (<1) 0 0 Nausea (grade 3) 0 0 1 (2) Immune-mediated nephritis (grade 3) 0 1 (1) 0 tholudes all participants who received 21 dose of study treatment One participant experienced grade 5 myelosuppression and 5 cohors platelet who count decreased One participant experienced grade 5 immune-mediated myositis includes all participants in dose escalation grade Numbers 2 and one participant in am 4 experienced grade 3 increases in both ALT and AST participant in received am 21 dose of study treatment and ether completed cycle 1 without a DLT or experienced a DLT in cycle 1. "One ALP, alkaine in the bar charts represent the total incidence of grade events for TRAEs with incidence DCO date 05JAN2026 phosphatase; ALT, alanine transaminase, AST, aspartate aminotransferase; GGT, gamma-glutamyltransferase >10% Organisers Partners ESMO IASLC INTERNATIONAL FOR THE or LUNG ESTRO I I ETOP-IBCSG /

OCR text not available for this slide. View the original post on X for context.

OCR text not available for this slide. View the original post on X for context.

OCR text not available for this slide. View the original post on X for context.

OCR text not available for this slide. View the original post on X for context.